Neuromethabolic therapy in patients with chronic cerebrovascular disorders

Cover Page

Cite item

Full Text

Abstract

Cerebrovascular diseases - the main cause of death and persistent disability. Prevention of cardiovascular diseases is the most effective way to solve the problem of vascular lesions of the brain. In the case of an already developed vascular lesion of the brain, an improvement in the outcome of the disease can be achieved by including neurometabolic drugs in the complex therapy. The clinical effects of L-carnitine (Elkar) in patients with acute and chronic cerebral ischemia are considered. It is noted that the maximum effect of its use can be achieved with the simultaneous use of non-drug treatment and adequate drug therapy.

About the authors

A. A Tyazhelnikov

City Consultative and Diagnostic Polyclinic №121 of the Department of Health of Moscow

канд. мед. наук, глав. врач 117042, Russian Federation, Moscow, Iuzhnobutovskaia ul., d. 87

Z. Kh Osmayeva

Chechen State University

ассистент каф. неврологии, нейрохирургии и медицинской генетики Медицинского института 364024, Russian Federation, Grozny, ul. A.Sheripova, d. 32

P. R Kamchatnov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: pavkam7@gmail.com
д-р мед. наук, проф. каф. неврологии, нейрохирургии и медицинской генетики лечебного фак-та 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

A. V Chugunov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

References

  1. Blinder P, Tsai P.S, Kaufhold J.P et al. The cortical angiome: an interconnected vascular network with noncolumnar patterns of blood flow. Nat Neurosci 2013; 16: 889-97. http://doi.org/10.1038/nn.3426
  2. Гулевская Т.С., Моргунов В.А. Патологическая анатомия нарушений мозгового кровообращения при атеросклерозе и артериальной гипертензии. М.: Медицина, 2009.
  3. Nishimura N, Rosidi N.L, Iadecola C, Schaffer C.B. Limitations of collateral flow after occlusion of a single cortical penetrating arteriole. J Cereb Blood Flow Metab 2010; 30: 1914-27. http://doi.org/10.1038/jcbfm.2010.157
  4. Kampoli A.M, Tousoulis D, Briasoulis A et al. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011; 17 (37): 4147-58.
  5. McLauchlan D, Malik G.A, Robertson N.P. Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment. J Neurol 2017; 264: 2184-6. https://doi.org/10.1007/s00415-017-8608-7
  6. Cooper L, Woodard T, Sigurdsson S et al. Cerebrovascular Damage Mediates Relations Between Aortic Stiffness and Memory. Hypertension 2016; 67: 176-82. https://doi.org/10.1161/HYPERTENSIONAHA.115.06398
  7. Pase M.P, Himali J.J, Mitchell G.F et al. Association of aortic stiffness with cognition and brain aging in young and middle-aged adults: the Framingham third generation cohort study. Hypertension 2016; 67 (3): 513-9. https://doi.org/10.1161/HYPERTENSIONAHA.115.06610
  8. Prystowsky E.N, Padanilam B.J. Preserve the Brain: Primary Goal in the Therapy of Atrial Fibrillation. J Am Coll Cardiol 2013; 62 (6): 540-2. doi: 10.1016/j.jacc.2013.04.038
  9. Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ 2018; 361: k1675. https://doi.org/10.1136/bmj.k1675
  10. Gusev E, Skvortsova V. Brain Ischemia. New York-Boston-Dordecht-London: Kluwer Academic/Plenum Publishers, 2003.
  11. Кузин В.М. Карнитина хлорид (25 лет в клинической практике). РМЖ. 2003; 11 (10): 5-9
  12. Суслина З.А., Федорова Т.Н., Максимова М.Ю., Ким Е.К. Антиоксидантная активность милдроната и L-карнитина при лечении пациентов с цереброваскулярными заболеваниями. Эксп. клин. фарм. 2003; 66 (3): 32-5.
  13. McMackin C, Widlansky M, Hamburg N et al. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich) 2007; 9 (4): 249-55.
  14. Volek J, Judelson D, Silvestre R et al. Effects of carnitine supplementation on flow-mediated dilation and vascular inflammatory responses to a high-fat meal in healthy young adults. Am J Cardiol 2008; 102 (10): 1413-7.
  15. Гусев Е.И., Кузин В.М., Колесникова Т.Н. и др. Карнитин - ведущий фактор регенерации нервной ткани. Мед. информационный вестн. 1999 (февраль): с. 11-23.
  16. Гусев Е.И., Скворцова В.И. Нейропротективная терапия ишемического инсульта. Нервные болезни. 2002; 1: 3-10.
  17. Попова Т.Е. Особенности развития и коррекции гипоксии у больных с ишемическим инсультом. Дис. … канд. мед. наук. М., 2001.
  18. Бодыхов М.К., Стаховская Л.В., Салимов К.А., Чер Сун И. Оценка безопасности и эффективности препарата «Элькар» (левокарнитин) у пациентов в остром периоде ишемического инсульта в каротидной системе. РМЖ. Неврология. Психиатрия. 2011; 19 (9): 3-8.
  19. Ferrari R, Merli E, Cicchitelli G et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci 2004; 1033: 79-91.
  20. Головкин В., Зуев А., Привалова М. и др. Когнитивные нарушения и кардиореспираторная дисфункция при дисциркуляторной энцефалопатии с кардиоцеребральным синдромом. Врач. 2018; 29 (4): 51-3. doi: 10.29296/25877305-2018-04-09
  21. Чичановская Л.В., Бахарева О.Н., Сорокина К.Б. Исследование безопасности и эффективности L-карнитина у больных в раннем восстановительном периоде ишемического инсульта. Журн. неврологии и психиатрии им. С.С.Корсакова. 2017; 12 (2): 65-9.
  22. Svoboda Z, Kvĕtina J, Herink J et al. Galantamine antiacetylcholinesterase activity in rat brain influenced by L-carnitine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149 (2): 335-7.
  23. Nałecz K, Miecz D, Berezowski V et al. Carnitine: transport and physiological functions in the brain. Mol Aspects Med 2004; 25 (5-6): 551-67.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies